摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,6-dihydro-1H-furo[3,4-c]pyrazole-3-carboxylic acid | 949034-59-7

中文名称
——
中文别名
——
英文名称
4,6-dihydro-1H-furo[3,4-c]pyrazole-3-carboxylic acid
英文别名
——
4,6-dihydro-1H-furo[3,4-c]pyrazole-3-carboxylic acid化学式
CAS
949034-59-7
化学式
C6H6N2O3
mdl
——
分子量
154.125
InChiKey
VBEOEILKNBIXDR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.7
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    75.2
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    4,6-dihydro-1H-furo[3,4-c]pyrazole-3-carboxylic acidN,N'-羰基二咪唑ammonium hydroxide 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 以42.3 %的产率得到4,6-dihydro-1H-furo[3,4-c]pyrazole-3-carboxamide
    参考文献:
    名称:
    WO2024141444A1
    摘要:
    公开号:
  • 作为产物:
    描述:
    ethyl 4,6-dihydro-1H-furo[3,4-c]pyrazole-3-carboxylate 生成 4,6-dihydro-1H-furo[3,4-c]pyrazole-3-carboxylic acid
    参考文献:
    名称:
    Agonist lead identification for the high affinity niacin receptor GPR109a
    摘要:
    A strategy for lead identification of new agonists of GPR109a, starting from known compounds shown to activate the receptor, is described. Early compound triage led to the formulation of a binding hypothesis and eventually to our focus on a series of pyrazole acid derivatives. Further elaboration of these compounds provided a series of 5,5-fused pyrazoles to be used as lead compounds for further optimization. (C) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.06.028
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS FOR THE TREATMENT OF HIV<br/>[FR] COMPOSÉS POUR TRAITER LE VIH
    申请人:GILEAD SCIENCES INC
    公开号:WO2013006738A1
    公开(公告)日:2013-01-10
    The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
    本发明提供了如下式(I)的化合物或其盐,还提供了包含如下式(I)化合物的药物组合物,制备如下式(I)化合物的方法,用于制备如下式(I)化合物的中间体以及治疗Retroviridae病毒感染的治疗方法,包括由HIV病毒引起的感染。
  • HETERO-FUSED CYCLIC COMPOUND
    申请人:EISAI R&D MANAGEMENT CO., LTD.
    公开号:US20160168176A1
    公开(公告)日:2016-06-16
    A compound represented by the formula (I) or a salt thereof: wherein a ring Z is a 5 to 6-membered heteroaromatic ring having one or two heteroatoms in the ring; X 1 is a hydrogen atom, a hydroxy group, a hydroxy C 1-6 alkyl group, —B(OH) 2 , a boronate ester group, a cyclic boronate ester group, a boranyl group, a cyclic boranyl group, —BF 3 M n1 , —Sn(R 12 )(R 13 )(R 14 ), a leaving group, a carboxy group, a formyl group, or —NR 16 R 17 ; and X 2 is a hydrogen atom or —CO 2 R 18 .
    一个由化学式(I)表示的化合物或其盐:其中环Z是一个具有一个或两个杂原子的5到6元杂芳香环;X1是氢原子、羟基、羟基C1-6烷基基团、—B(OH)2、硼酸酯基团、环硼酸酯基团、硼烷基团、环硼烷基团、—BF3Mn1、—Sn(R12)(R13)(R14)、一个离去基团、一个羧基、一个甲酰基,或—NR16R17;而X2是氢原子或—CO2R18。
  • COMPOUNDS FOR THE TREATMENT OF HIV
    申请人:Bondy Steven S.
    公开号:US20140142085A1
    公开(公告)日:2014-05-22
    The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
    本发明提供了以下式子(I)的化合物或其盐,如本文所述。本发明还提供了包括式子(I)化合物的制药组合物,制备式子(I)化合物的方法,用于制备式子I化合物的中间体以及治疗逆转录病毒感染的治疗方法,包括由HIV病毒引起的感染。
  • HETERO-CONDENSED RING COMPOUND
    申请人:Eisai R&D Management Co., Ltd.
    公开号:EP3026054A1
    公开(公告)日:2016-06-01
    A compound represented by the formula (I) or a salt thereof: wherein a ring Z is a 5 to 6-membered heteroaromatic ring having one or two heteroatoms in the ring; X1 is a hydrogen atom, a hydroxy group, a hydroxy C1-6 alkyl group, -B(OH)2, a boronate ester group, a cyclic boronate ester group, a boranyl group, a cyclic boranyl group, -BF3Mn1, -Sn(R12)(R13)(R14), a leaving group, a carboxy group, a formyl group, or -NR16R17; and X2 is a hydrogen atom or -CO2R18.
    式 (I) 所代表的化合物或其盐: 其中环 Z 是 5 至 6 元杂芳环,环中有一个或两个杂原子;X1是氢原子、羟基、羟基 C1-6烷基、-B(OH)2、硼酸酯基、环硼酸酯基、硼烷基、环硼烷基、-BF3Mn1、-Sn(R12)(R13)(R14)、离去基团、羧基、甲酰基或-NR16R17;以及 X2是氢原子或-CO2R18。
  • Compounds for the treatment of HIV
    申请人:Gilead Sciences, Inc.
    公开号:US10370358B2
    公开(公告)日:2019-08-06
    The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
    本发明提供如本文所述的式(I)化合物或其盐。本发明还提供了包含式(I)化合物的药物组合物、制备式(I)化合物的工艺、用于制备式(I)化合物的中间体以及治疗逆转录病毒科病毒感染(包括由 HIV 病毒引起的感染)的治疗方法。
查看更多